About pCPA

Overview
History
Vision and Mandate
Where pCPA Fits in the Process
pCPA Office

 

Overview

Through collective negotiations, the pan-Canadian Pharmaceutical Alliance has realized overall savings (as of March 31, 2021) of $2.16 billion annually for brand name drugs and $740 million annually for generic drugs totalling $2.90 billion in annualized savings.

History

The pCPA was originally established as the pan-Canadian Pricing Alliance in August 2010. It was created by the premiers of Canada though the Council of the Federation’s Health Care Innovation Working Group. The aim was to achieve greater value for publicly funded drug programs and patients through the combined negotiating power of participating jurisdictions.

In 2015, the alliance was formalized with the new name pan-Canadian Pharmaceutical Alliance, a mandate and objectives were developed, a governance structure was implemented, and an office was created to provide support to the member jurisdictions. Also, in 2015, Quebec joined the alliance and in 2016, the federal drug plans joined.

pCPA member jurisdictions include public drug plan participation from: British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Québec, New Brunswick, Nova Scotia, Prince Edward Island, Newfoundland & Labrador, Yukon, Northwest Territories, Nunavut, Non-Insured Health Benefits (NIHB), Correctional Services of Canada (CSC) and Veterans Affairs Canada (VAC)

Vision and Mandate 

Vision: To demonstrate collective leadership through value-driven investments in effective treatments that improve the health of Canadians and preserve a sustainable publicly funded health system in Canada. 

Mandate: To conduct collective, expert-informed negotiations and achieve the pCPA objectives:

  • increase access to relevant and cost-effective treatments;
  • achieve consistent and  lower drug costs;
  • reduce duplication and optimize resource utilzation; and 
  • improve consistency in funding decisions.

Where pCPA fits in the Canadian Drug Review and Approval Process

pCPA is one part of the overall Canadian drug approval and reimbursement process.

Where pCPA fits*Please note that the figure above is a simplified illustration of the process and there can be exceptions.

 

Health Canada

Health Canada reviews drugs for safety, efficacy and quality before authorizing them for sale in Canada.

 

CADTH & INESSS

In Canada there are two health technology assessment organizations which review the clinical and cost-effectiveness of a drug product; the Canadian Agency for Drugs and Technologies in Health (CADTH) and in Quebec, l’Institut national d’excellence en santé et en services sociaux (INESSS). CADTH and INESSS provide a recommendation to public drug plans on whether or not a drug should be reimbursed for public funding.

pCPA

The pCPA negotiation process begins for the majority of new drugs, once a recommendation is published by CADTH and/or INESSS. pCPA uses the recommendations from CADTH and INESSS and other factors to determine whether or not it will enter into a negotiation for a drug. Following a successful negotiation, pCPA will issue a letter of intent which sets the terms of the agreement between pCPA and the drug manufacturer.

Public Drug Plans

Public Drug Plans make a final decision to fund a drug once a negotiation has been successfully completed and enters into its own separate agreement with the drug manufacturer.

 

pCPA Office

The pCPA office is hosted and staffed through Ontario and works closely with the jurisdictions providing support in negotiations, administration, communications, standardization, analytics, process design, and policy related to brand and generic products.

Corporate & Leadership
Senior Manager

Dominic Tan

  Senior Communications Advisor

Joanne Woodward Fraser

  Strategic Planning and Business Optimization Lead

Rohini Basur

  Negotiations Consultant

Position to be filled 

  Administrative Assistant

Shawna Robertson

Brand Drugs
Team Lead 

Satyam Merja

  Senior Pharmacists

Jane Lui

Position to be filled

  Senior Negotiators

Anchalee Srisombun

Michael Taylor

  Senior Program Analyst:

Aastha Gulati

  Negotiations Consultant:

Position to be filled

  Program Analyst:

Tayyab Pirzada

  Administrative Assistant

Kerri-Ann Cushnie

  Financial Consultant

Jaya Venkatesh

Generic Drugs
Senior Economist

Daniel Sperber

  Senior Program Analyst

Position to be filled 

  Administrative Assistant

Jacqueline Bailey

Analytics & Strategy
Senior Economist

Daniel Sperber

  Negotiations Consultant

Andrew Girgis

  Senior Health Economists:

Mirhad Loncar

Josh Dubé

  Health Economists:

Chanh-Phong Tran